BCL2 and cutaneous melanoma: Previously, the presence of the Δ133p53β isoform was predicted to define poorer outcomes in patients with cutaneous melanoma [38], also in virtue of its ability to antagonize p53-mediated apoptosis, inducing the expression of anti-apoptotic BCL-2 family members [51].